Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalo Therapeutics, Inc.AVTX · Entity 4936 | Director | June 02, 2026 | June 04, 2026 |
| CELGENE CORP /DE/CELG · Entity 15781 | Director | May 18, 2018 | May 21, 2018 |
| Tyra Biosciences, Inc.TYRA · Entity 4680 | Director | March 25, 2026 | March 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalo Therapeutics, Inc.
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.96 · Expires 2036-06-02 | Direct | 20,100 |
Reported balance
After 2026-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 20,100 · Balance 20,100 F1: The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date.
CELGENE CORP /DE/
Report date May 18, 2018 · Filed May 21, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 76,301 |
Ending reported balance
After 2018-05-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-05-18 · Exercise / conversion · Acquired 27,750 · Balance 104,051 Row 2 · 2018-05-18 · Sale · Disposed 27,750 · Balance 76,301 F1: The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $78.62 to $78.74, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.01 · Expires 2018-06-18 | Direct | 0 |
Reported balance
After 2018-05-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-18 · Exercise / conversion · Disposed 27,750 · Balance 0 F3: The option was issued pursuant to the Company's 1995 Non-Employee Director's Incentive Plan. F2: The option was fully exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $78.62 to $78.74, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2: The option was fully exercisable.
F3: The option was issued pursuant to the Company's 1995 Non-Employee Director's Incentive Plan.
Tyra Biosciences, Inc.
Report date March 25, 2026 · Filed March 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,526 |
Reported balance
After 2026-03-25 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-03-25 · Exercise / conversion · Acquired 14,295 · Balance 42,526 |
| Common StockSEC Table I · non-derivative | Direct | 28,231 |
Reported balance
After 2026-03-25 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-03-25 · Sale · Disposed 14,295 · Balance 28,231 F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.95 to $37.11. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Common StockSEC Table I · non-derivative | Direct | 81,403 |
Reported balance
After 2026-03-26 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-03-26 · Exercise / conversion · Disposed 53,172 · Balance 81,403 |
| Common StockSEC Table I · non-derivative | Direct | 28,231 |
Reported balance
After 2026-03-26 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-03-26 · Disposition to issuer · Disposed 53,172 · Balance 28,231 F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.25 to $38.125. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2031-03-09 | Direct | 53,172 |
Reported balance
After 2026-03-25 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-25 · Exercise / conversion · Disposed 14,295 · Balance 53,172 F3: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2031-03-09 | Direct | 0 |
Reported balance
After 2026-03-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-26 · Exercise / conversion · Disposed 53,172 · Balance 0 F3: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.95 to $37.11. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.25 to $38.125. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2017 Filed Jul 5, 2017 19:32 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 734 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-043765 · doc4.xml · derivative · entry 2 KAPLAN GILLA · CIK 0001247024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 734 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on July 1, 2014 vested and such vested portion of the restricted stock units settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan (as amended and restated on April 15, 2015)). F1 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on July 1, 2014 vested and such vested portion of the restricted stock units settled for shares of the Company's common stock. F1 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on July 1, 2014 vested and such vested portion of the restricted stock units settled for shares of the Company's common stock. Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 19:32 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 734 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-043765 · doc4.xml · nonDerivative · entry 1 KAPLAN GILLA · CIK 0001247024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: One-third of the restricted stock units granted to the reporting person on July 1, 2014 vested and such vested portion of the restricted stock units settled for shares of the Company's common stock. Read SEC document |
| June 17, 2017 Filed Jun 20, 2017 16:08 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-041067 · doc4.xml · derivative · entry 2 KAPLAN GILLA · CIK 0001247024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334 Underlying: Common Stock · 333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on June 17, 2015 vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_price: The balance of the restricted stock units will vest on June 17, 2018. Vested shares will be delivered to the reporting person promptly after the vesting date. F4 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan (as amended and restated on April 15, 2015)). F1 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on June 17, 2015 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on June 17, 2015 vested and settled for shares of the Company's common stock. Read SEC document |
| June 17, 2017 Filed Jun 20, 2017 16:08 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-041067 · doc4.xml · nonDerivative · entry 1 KAPLAN GILLA · CIK 0001247024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,067 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: One-third of the restricted stock units granted to the reporting person on June 17, 2015 vested and settled for shares of the Company's common stock. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 16:09 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040459 · doc4.xml · derivative · entry 4 KAPLAN GILLA · CIK 0001247024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750 Underlying: Common Stock · 375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F7 · derivative.exercise_price: The remainder of the restricted stock units will vest as follows: 375 shares on June 15, 2018; 375 shares on June 15, 2019. Vested shares will be delivered to the reporting person promptly after the vesting date. F6 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 16:09 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040459 · doc4.xml · nonDerivative · entry 1 KAPLAN GILLA · CIK 0001247024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: One-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 16:09 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040459 · doc4.xml · derivative · entry 3 KAPLAN GILLA · CIK 0001247024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 Underlying: Common Stock · 900 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F6 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F5 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments commencing on June 14, 2018. Vested shares will be delivered to the reporting person promptly after the vesting date. F5 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments commencing on June 14, 2018. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 16:09 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $121.04 | $0.00 |
DisclosureSEC source: 0001209191-17-040459 · doc4.xml · derivative · entry 2 KAPLAN GILLA · CIK 0001247024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2027-06-14 F3 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F2 · derivative.exercise_date: Option is immediately exercisable and will vest on the earlier of June 14, 2018 or the day preceding the date of the next annual stockholder meeting. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 16:11 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionStock Option (right to buy) · Derivative | 9,250 | $0.00 Strike: $28.97 | $0.00 |
DisclosureSEC source: 0001209191-17-037189 · doc4.xml · derivative · entry 2 KAPLAN GILLA · CIK 0001247024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,250 shares Expires 2017-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The option was issued pursuant to the Company's 1995 Non-Employee Director's Incentive Plan. F1 · derivative.exercise_date: The option was fully exercisable. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 16:11 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 9,250 | $28.97 | $267,926.25 |
DisclosureSEC source: 0001209191-17-037189 · doc4.xml · nonDerivative · entry 1 KAPLAN GILLA · CIK 0001247024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 30, 2017 Filed Mar 31, 2017 17:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | SaleCommon Stock | 14,033 | $123.83 | $1,737,706.39 |
DisclosureSEC source: 0001209191-17-023918 · doc4.xml · nonDerivative · entry 1 KAPLAN GILLA · CIK 0001247024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,109 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $123.76 to $123.92, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 16:37 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionStock Options (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $25.58 | Not disclosed |
DisclosureSEC source: 0001209191-17-018752 · doc4.xml · derivative · entry 2 KAPLAN GILLA · CIK 0001247024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2017-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The option was issued pursuant to the Company's 1995 Non-Employee Director's Incentive Plan. F1 · derivative.exercise_date: The option was fully exercisable. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 16:37 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 7,500 | $25.58 | $191,812.50 |
DisclosureSEC source: 0001209191-17-018752 · doc4.xml · nonDerivative · entry 1 KAPLAN GILLA · CIK 0001247024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2016 Filed Sep 20, 2016 16:42 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $29.26 | $0.00 |
DisclosureSEC source: 0001209191-16-142165 · doc4.xml · derivative · entry 2 KAPLAN GILLA · CIK 0001247024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2016-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The option was issued pursuant to the Company's 1995 Non-Employee Director's Incentive Plan. F1 · derivative.exercise_date: The option was fully exercisable. Read SEC document |
| September 19, 2016 Filed Sep 20, 2016 16:42 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 7,500 | $29.26 | $219,450.00 |
DisclosureSEC source: 0001209191-16-142165 · doc4.xml · nonDerivative · entry 1 KAPLAN GILLA · CIK 0001247024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,642 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2016 Filed Sep 16, 2016 16:15 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | SaleCommon Stock | 9,710 | $106.44 | $1,033,532.40 |
DisclosureSEC source: 0001209191-16-141774 · doc4.xml · nonDerivative · entry 1 KAPLAN GILLA · CIK 0001247024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,142 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $106.26 to $106.66, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.